Merck's Keytruda Survives 'Conflicted' Adcom Vote For Bladder Cancer Indication
Many Oncologic Drugs Advisory Committee members struggled to decide whether the data showed a clinically meaningful benefit in the proposed bladder cancer indication.
You may also be interested in...
Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Keytruda's Proposed Bladder Cancer Indication: Is Delaying Cystectomy Really A Benefit?
Oncologic Drugs Advisory Committee members wondered when Keytruda should be used since cystectomy can be curative and waiting could make the surgery more difficult.
Merck, ODAC Mostly Like US FDA's Point-Counterpoint Briefing Document
Tweaks to the combined advisory committee briefing document such as appendices with quality of life or other commonly requested information may be needed.